Cathie Wood
PRME icon

Cathie Wood’s Prime Medicine PRME Stock Holding History

Cathie Wood’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8M Buy
8,348,746
+2,101,919
+34% +$6.98M 0.2% 80
2026
Q1 		$21.7M Buy
6,246,827
+878,301
+16% +$3.34M 0.17% 77
2025
Q4 		$18.6M Sell
5,368,526
-109,325
-2% -$486K 0.12% 90
2025
Q3 		$30.3M Buy
5,477,851
+3,155,182
+136% +$12.8M 0.18% 75
2025
Q2 		$5.74M Sell
2,322,669
-772,503
-25% -$1.19M 0.04% 104
2025
Q1 		$6.16M Sell
3,095,172
-2,055,061
-40% -$5.24M 0.06% 104
2024
Q4 		$15M Sell
5,150,233
-510,486
-9% -$1.79M 0.13% 77
2024
Q3 		$21.9M Sell
5,660,719
-466,054
-8% -$2.16M 0.2% 62
2024
Q2 		$31.5M Buy
6,126,773
+133,419
+2% +$809K 0.28% 54
2024
Q1 		$42M Buy
5,993,354
+2,855,084
+91% +$21.7M 0.29% 51
2023
Q4 		$27.8M Buy
3,138,270
+515,841
+20% +$3.97M 0.16% 68
2023
Q3 		$25M Buy
2,622,429
+173,230
+7% +$2.25M 0.19% 64
2023
Q2 		$35.9M Buy
2,449,199
+526,922
+27% +$7.36M 0.24% 51
2023
Q1 		$23.6M Buy
1,922,277
+282,293
+17% +$4.6M 0.16% 65
2022
Q4 		$30.5M Buy
+1,639,984
New +$29.6M 0.26% 52

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cathie Wood's PRME Position: Q2 2026 in Review

Cathie Wood increased its Prime Medicine (PRME) stake by 34% in Q2 2026, buying an estimated $6.98M and bringing the position to 8,348,746 shares worth $30.8M. The position accounts for 0.2% of the portfolio, ranked #80.

Cathie Wood first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $42M in Q1 2024. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Cathie Wood held 8,348,746 shares of Prime Medicine worth $30.8M as of Q2 2026.
  • Cathie Wood bought 2,101,919 Prime Medicine shares in Q2 2026, an estimated $6.98M.
  • Prime Medicine made up 0.2% of Cathie Wood's portfolio in Q2 2026, its #80 holding.
  • Cathie Wood first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • Cathie Wood's Prime Medicine position peaked at $42M in Q1 2024.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on ARK Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.